Agenus Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $114.2K | $103.5K | $156.3K | $98.0K | $295.7K | $88.2K | $150.0K | $36.8K |
| Product revenue | $4.2K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Grant revenue | $0 | $0 | $0 | $0 | $184 | $91 | $1.3K | $0 |
| Service revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Research and development revenue (legacy pre-ASC606 aggregate) | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| License fees and milestones | $0 | $0 | $25.0K | $5.0K | $220.0K | $22.9K | $75.5K | $14.0K |
| Royalty sales milestone | $0 | $0 | $0 | $25.3K | $0 | $0 | $15.1K | $0 |
| Research and development services | $0 | $0 | $1.4K | $1.7K | $1.5K | $754 | $1.7K | $4.2K |
| Clinical product revenue | $334 | $482 | $116 | $762 | $587 | $0 | $0 | $0 |
| Manufacturing services | $0 | $0 | $0 | $0 | $0 | $0 | $3.3K | $0 |
| Other services | $1.0K | $2.0K | $3.0K | $10.5K | $6.7K | $4.6K | $0 | $0 |
| Recognition of deferred R&D revenue | $0 | $0 | $12.2K | $9.5K | $22.4K | $12.3K | $22.6K | $1.3K |
| Non-cash royalty revenue | $108.6K | $101.0K | $114.6K | $45.3K | $44.4K | $47.5K | $30.4K | $17.3K |
| Cost of Revenue | $1.0M | $486.0K | $3.1M | $10.6M | $3.5M | $2.3M | — | — |
| Gross Profit | $-907.8K | $-382.5K | $-3.0M | $-10.5M | $-3.2M | $-2.3M | — | — |
| Gross Margin | -795.0% | -369.7% | -1,890.2% | -10,681.0% | -1,073.6% | -2,564.2% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $79.3M | $155.5M | $234.6M | $186.7M | $178.6M | $142.6M | $168.3M | $124.6M |
| SG&A Expense | $54.4M | $71.9M | $78.7M | $81.0M | $76.4M | $59.2M | $46.0M | $37.3M |
| Operating Income | $-20.2M | $-120.5M | $-159.5M | $-179.4M | $25.7M | $-117.2M | $-70.1M | $-123.8M |
| Operating Margin | -17,661.7% | -116,442.6% | -102,069.6% | -183,043.9% | 8,708.2% | -132,964.7% | -46,743.0% | -336,616.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-3.1M | $-232.3M | $-257.4M | — | — | — | — | — |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | $-3.1M | $-232.3M | $-257.4M | $-230.7M | $-28.7M | $-182.9M | $-111.6M | $-162.0M |
| Net Margin | -2,699.7% | -224,496.7% | -164,692.2% | -235,305.6% | -9,715.0% | -207,430.1% | -74,349.5% | -440,528.5% |
| EPS (Basic) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $0.00 | $-0.02 | $-0.01 | $-0.02 |
| EPS (Diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $0.00 | $-0.02 | $-0.01 | $-0.02 |
| Shares Outstanding (Basic) | 29.7M | 21.5M | 17.9M | 14.1M | 14.2M | 10.7M | 8.32B | 6.36B |
| Shares Outstanding (Diluted) | 29.7M | 21.5M | 17.9M | 14.1M | 14.2M | 10.7M | 8.32B | 6.36B |
| Dividends Per Share | — | — | — | — | — | — | — | — |